Zobrazeno 1 - 8
of 8
pro vyhledávání: '"G. J. Conard"'
Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent
Autor:
Gregory Granrud, J Krejci, Richard W. Asinger, Morrison Hodges, G J Conard, Frank L. Mikell, J M Haugland
Publikováno v:
Circulation. 65:879-885
Flecainide acetate, a new antiarrhythmic agent, was given orally to 11 hospitalized patients with chronic high-frequency ventricular ectopic depolarizations. Drug effectiveness was evaluated with a dose-ranging single-blind protocol, which included p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5e865bca7e78a9c0541e4bc48f5ea72
https://doi.org/10.1161/01.cir.65.5.879
https://doi.org/10.1161/01.cir.65.5.879
Autor:
E. H. Banitt, G. J. Conard
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 18:713-720
N-(2-Piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide acetate (flecainide acetate; R-818), a new antiarrhythmic agent, was labelled with carbon-14 at the carboxamide position for metabolic studies. A three-step synthetic route starting from 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c16ae69c6df35afd58a01b475a94c76
https://doi.org/10.1002/jlcr.2580180513
https://doi.org/10.1002/jlcr.2580180513
Autor:
R L, McQuinn, G J, Quarfoth, J D, Johnson, E H, Banitt, S V, Pathre, S F, Chang, R E, Ober, G J, Conard
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 12(4)
The metabolism of 14C-flecainide acetate, a new antiarrhythmic, was investigated in four healthy human subjects, after a single, 200-mg oral dose. The cumulative recovery of radioactivity ranged from 81 to 90% (mean, 86%) in urine and from 4 to 6% (m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b817388ce6ed8081a0c1e2386ade2f8d
https://pubmed.ncbi.nlm.nih.gov/6148206
https://pubmed.ncbi.nlm.nih.gov/6148206
Publikováno v:
Arzneimittel-Forschung. 32(2)
To assess the relationship between plasma levels of 2,5-bis-(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)benz-amide acetate (flecainide acetate), a new antiarrhythmic, and the suppression of ventricular arrhythmias, a decreasing multiple oral dosage
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9fb79966e24cc4a9b5e4339ad4cd4baa
https://pubmed.ncbi.nlm.nih.gov/7199921
https://pubmed.ncbi.nlm.nih.gov/7199921
Publikováno v:
Arzneimittel-Forschung. 33(2)
A fluorometric method for the quantitation of 2,5-bis-(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)benzamide acetate (R-818, flecainide acetate) in human plasma has been developed. The minimum quantifiable concentration of flecainide acetate by this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3bc16229a1a79dde6c29ecdf1075d6d8
https://pubmed.ncbi.nlm.nih.gov/6682665
https://pubmed.ncbi.nlm.nih.gov/6682665
Publikováno v:
Clinical pharmacology and therapeutics. 44(5)
The pharmacokinetics of flecainide were studied in six patients with cirrhosis of the liver and in six healthy subjects after a single 2 mg/kg intravenous dose. Hepatic biotransformation capability before flecainide dosing was assessed by antipyrine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdcffd28b2da3d7722c3aef53e796970
https://pubmed.ncbi.nlm.nih.gov/3141098
https://pubmed.ncbi.nlm.nih.gov/3141098
Publikováno v:
Journal of biomedical materials research. 13(1)
The release of monomer from methylmethacrylate bone cements was studied during immersion in an aqueous environment intended to simulate in vivo polymerization of the material. Monomer release from disk-shaped specimens into an aqueous environment was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c70b8c78a64754a9685eddccafdbbdfc
https://pubmed.ncbi.nlm.nih.gov/429381
https://pubmed.ncbi.nlm.nih.gov/429381
Publikováno v:
Clinical therapeutics. 6(5)
Flecainide, a new antiarrhythmic agent, was given to eight healthy men to ascertain plasma drug levels and to assess tolerance for the drug. Each subject received a single intravenous (IV) dose (0.5, 1, 1.5, or 2 mg/kg) of flecainide, and plasma leve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::381058db465c5524801bdfebf16cc148
https://pubmed.ncbi.nlm.nih.gov/6478470
https://pubmed.ncbi.nlm.nih.gov/6478470